돼지의 호흡기질병을 효과적으로 치료 및 예방하고자 Enrofloxacin(Baytril premix)를 사료에 혼합하여 호흡기질병이 산발적으로 발생하고 있는 돈군에 투여하여 호흡기질병의 치료여부, 증체량, 사료요구율, 폐병변치 등을 조사하여 다음과 같은 결과를 얻었다. 1. 육성돈군에 Enrofloxacin(Baytril premix)를 10일간 급여하였던 바 증체량은 33일동안 31kg이었으나 대조구에서는 20.5kg으로써 통계적 유의차를 보였으며(p<0.05), 사료요구율도 개선되었고(p<0.05), 호흡기질병의 임상증상도 없어졌다. 2. 폐병변조사에서 Baytril 급여구에서는 평균 폐병변의 형성정도는 전체 폐면적의 7.92%이었으나 대조구에서는 15.8%의 심한 병변이 형싱되어 있었다. 3. 공시농장에서 발생하고 있는 호흡기질병은 Actinobacillus pleuropneumoniae에 의한 흉막폐렴, Mycoplasma성 유행성폐렴 및 Pasteurella multocida에 의한 폐렴 등이었다.
For the purpose of effective treatment and prevention of porcine respiratory diseases, Enrofloxacin(Baytril premix) was administered in the feed to trial herd occurred sporadically the respiratory diseases and then a serious investigation was carried out on the therapeutic effect, weight gain, feed conversion rate and lung lesion scoring. The results obtained were as follows, 1. The grower pigs which were administered with Baytril premix for 10 days gained the average body weight of 31kg for 33 days compared to 20.5kg of control group(p<0.05). Also drastical improvement of feed conversion rate(p<0.05) and disappearance of clinical signs were approved. 2. Average scorings of lung lesions were 7.92% in the medication group and 15.8% in the control group respectively. 3. Respiratory diseases outbreaked in the trial farm were pleuropneumonia caused by Actinobacillus (Haemophilus)pleuropneumoniae, Mycoplasmal pneumonia and Pasteurellosis.
